We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Renin-Angiotensin System in Essential Hypertension

This study has been terminated.
(Insufficient accrual rate)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00141583
First Posted: September 1, 2005
Last Update Posted: June 9, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
St George's, University of London
  Purpose
Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.

Condition Intervention
Hypertension Drug: Enalapril 20 mg bd Drug: Candesartan 8 mg bd

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: The Renin-Angiotensin System in Essential Hypertension

Resource links provided by NLM:


Further study details as provided by St George's, University of London:

Primary Outcome Measures:
  • Change in BP
  • Change in PRA and aldosterone

Estimated Enrollment: 11
Study Start Date: April 2004
Study Completion Date: October 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Essential Hypertension
  • SBP 140-159 mmHg
  • DBP 90-99 mmHg

Exclusion Criteria:

  • Intolerance of or allergy to ACE Inhibitors or ARBS
  • Pregnant or Breastfeeding
  • Pre-menopausal women
  • Uncontrolled cardiac or renal failure
  • Diabetes mellitus
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00141583


Locations
United Kingdom
Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL
London, United Kingdom, SW17 0RE
Sponsors and Collaborators
St George's, University of London
Investigators
Principal Investigator: Timothy WR Doulton, BSc MRCP SGUL
  More Information

ClinicalTrials.gov Identifier: NCT00141583     History of Changes
Other Study ID Numbers: LREC 01.87.10
First Submitted: August 31, 2005
First Posted: September 1, 2005
Last Update Posted: June 9, 2015
Last Verified: May 2007

Keywords provided by St George's, University of London:
Renin-angiotensin system
ACE Inhibitor
Angiotensin Receptor Blocker

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Candesartan
Enalapril
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors